Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.
35 Analysts have issued a AstraZeneca forecast:
35 Analysts have issued a AstraZeneca forecast:
Mar '25 |
+/-
%
|
||
Revenue | 40,042 40,042 |
15%
15%
|
|
Gross Profit | 32,978 32,978 |
16%
16%
|
|
EBITDA | 12,459 12,459 |
30%
30%
|
EBIT (Operating Income) EBIT | 9,631 9,631 |
42%
42%
|
Net Profit | 5,660 5,660 |
23%
23%
|
In millions GBP.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Head office | United Kingdom |
CEO | Pascal Soriot |
Employees | 94,300 |
Founded | 1992 |
Website | www.astrazeneca.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.